AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-23. Numbers and descriptions here follow the published literature rather than marketing material.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
On the same day, Taliban-run Afghan Ministry of Defense said that they launched drones attack targeting military sites in Kohat, claiming to have inflicted significant losses. Later on, the ministry said that it had used two drones to strike a military facility near Islamabad. Pakistani officials denied the Taliban officials' claims and said that rudimentary drones had been intercepted and shot down in Kohat and Islamabad, injuring two civilians. They attributed the attacks to the Pakistani Taliban. In Pakistan's provincial capital of Quetta, two civilians were injured as result of falling debris from an intercepted drone, while in Lakki Marwat, six Pakistani police personnel were killed in a roadside bomb blast. The attack in Lakki Marwat was the deadliest in Pakistan since the onset of hostilities, although no group claimed responsibility for it.
An X-ray of swallowed barium may be used to reveal the size and shape of the esophagus, and the presence of any masses. The esophagus may also be imaged using a flexible camera inserted into the esophagus, in a procedure called an endoscopy. If an endoscopy is used on the stomach, the camera will also have to pass through the esophagus. During an endoscopy, a biopsy may be taken. If cancer of the esophagus is being investigated, other methods, including a CT scan, may also be used.
== Structure == Typical tandem mass spectrometry instrumentation setups include triple quadrupole mass spectrometer (QqQ), multi-sector mass spectrometer, ion trap, quadrupole–time of flight (Q-TOF), Fourier transform ion cyclotron resonance (FT-ICR), and hybrid mass spectrometers.
Sources: en.wikipedia.org
== Medical uses == Second generation cephalosporins are more effective in treating Gram-negative bacilli compared to first generation cephalosporins, which have a greater coverage for Gram-positive cocci. Also, it has been reported that cefuroxime is resistant to hydrolysis by β-lactamases produced by Gram-negative bacteria. Some medical uses are:
=== August === 6 August – Tom O'Connor, journalist, author, senior citizens' advocate and local politician, president of Grey Power (2016–2018), Waimate District Councillor (since 2013) (born 1944). 8 August Judy Bailey, pianist, composer, jazz musician and educator (Sydney Conservatorium of Music), and television presenter (Play School) (born 1935). Peter Lester, sailor, sailing coach and commentator, OK dinghy world champion (1977), Admiral's Cup winner (1987, 1993) (born 1954). 10 August – Patrick Waddington, Russian linguist, literary critic and historian (Victoria University of Wellington) (born 1934). 13 August – Grant Tavinor, philosopher (Lincoln University) (born c. 1973). 15 August – John Rowan, lawyer, King's Counsel (since 1997) (born 1944). 16 August – Janet Grieve, biological oceanographer (New Zealand Oceanographic Institute, NIWA), New Zealand Association of Scientists president (1998–2000), World Association of Copepodologists president (2008–2011) (born 1940). 17 August – John Bartley, cinematographer (Lost, The X Files, The Chronicles of Riddick), Emmy Award (1996) (born 1947). 18 August Lloyd Ashby, rugby union player (Southland, national team) (born 1931). Lindsay Sparks, cricketer (Central Districts, Auckland) and rugby union player (Marlborough) (born 1944). 19 August – Tony Smith, legal scholar (University of Reading, University of Cambridge, Victoria University of Wellington) (born 1947). 21 August Evelyn Attwood, tennis player (born 1924). Keith Nelson, rugby union player (Otago, Auckland, national team) and dentist (born 1938).
=== Cation exchange === Cation exchange sorbents are derivatized with functional groups that interact and retain positively charged cations, such as bases. Strong cation exchange sorbents contain aliphatic sulfonic acid groups that are always negatively charged in aqueous solution, and weak cation exchange sorbents contain aliphatic carboxylic acids, which are charged when the pH is above about 5. Strong cation exchange sorbents are useful because any strongly basic impurities in the sample will bind to the sorbent and usually will not be eluted with the analyte of interest; to recover a strong base a weak cation exchange cartridge should be used. To elute the analyte from either the strong or weak sorbent, the stationary phase is washed with a solvent that neutralizes ionic interaction between the analyte and the stationary phase.
called Duck and Cover, in which a turtle demonstrates how to protect oneself from the immediate effects of an atomic bomb explosion by using a coat, tablecloths, or even a newspaper. Recognizing that existing medical capacity would not be sufficient in an emergency, dentists were called upon to either assist physicians in an emergency or, if necessary, to provide assistance themselves. To mobilize the profession with the help of a prominent representative, dentist Russell Welford Bunting (1881-1962), dean of the University of Michigan Dental School, was recruited in July 1951 as a dental consultant to the USFCDA. The American physicist Karl Ziegler Morgan (1907-1999) was one of the founders of radiation health physics. In later life, after a long career with the Manhattan Project and Oak Ridge National Laboratory (ORNL), he became a critic of nuclear power and nuclear weapons production. Morgan was Director of Health Physics at ORNL from the late 1940s until his retirement in 1972. In 1955, he became the first president of the Health Physics Society and served as editor of the journal Health Physics from 1955 to 1977. Nuclear fallout shelters are designed to protect for an extended period. Due to the nature of nuclear warfare, such shelters must be completely self-sufficient for long periods. In particular, because of the radioactive contamination of the surrounding area, such a facility must be able to survive for several weeks. In 1959, top-secret construction began in Germany on a government bunker in the Ahr valley.
Sources: en.wikipedia.org
== Further reading == Breslau-Siderius, E. J.; et al. (1998). "Brack syndrome: a rare combination of bone fragility and multiple congenital joint contractures". Journal of Pediatric Orthopaedics B. 7 (1): 35–38. doi:10.1097/01202412-199801000-00006.
VWF is named after Erik Adolf von Willebrand, a Finnish physician who in 1926 first described a hereditary bleeding disorder in families from Åland. Although von Willebrand did not identify the definite cause, he distinguished von Willebrand disease (vWD) from hemophilia and other forms of bleeding diathesis. In the 1950s, vWD was shown to be caused by a plasma factor deficiency (instead of being caused by platelet disorders), and, in the 1970s, the VWF protein was purified. Harvey J. Weiss and coworkers developed a quantitative assay for VWF function that remains a mainstay of laboratory evaluation for VWD to this day.
Osteogenesis imperfecta is a group of genetic disorders, all of which cause bone fragility. OI has high genetic heterogeneity, that is, many different genetic mutations lead to the same or similar sets of observable symptoms (phenotypes). The main causes for developing the disorder are a result of mutations in the COL1A1 and/or COL1A2 genes which are jointly responsible for the production of collagen type I. Approximately 90% of people with OI are heterozygous for mutations in either the COL1A1 or COL1A2 genes. There are several biological factors that are results of the dominant form of OI. These factors include: intracellular stress; abnormal tissue mineralization; abnormal cell-to-cell interactions; abnormal cell-matrix interactions; a compromised cell matrix structure; and, abnormal interaction between non-collagenous proteins and collagen. Previous research led to the belief that OI was an autosomal dominant disorder with few other variations in genomes. However, with the lowering of the cost of DNA sequencing in the wake of 2003's Human Genome Project, autosomal recessive forms of the disorder have been identified. Recessive forms of OI relate heavily to defects in the collagen chaperones responsible for the production of procollagen and the assembly of the related proteins. Examples of collagen chaperones that are defective in patients with recessive forms of OI include chaperone HSP47 (Cole-Carpenter syndrome) and FKBP65. Mutations in these chaperones result in an improper folding pattern in the collagen 1 proteins, which causes the recessive form of the disorder.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.